HFA Transition Provides an Opportunity to Improve Aerobid®
Inhaler
Trudell ramps up production of AEROCOUNT®
Dose Indicator in preparation to supply Forest Laboratories, Inc. with
commercial volumes to support their CFC to HFA transition on Flunisolide
Inhalation Aerosol.
LONDON, Ontario (Business Wire EON/PRWEB ) September 23, 2008 --
Trudell Medical International is pleased to announce the selection of
the AEROCOUNT®
Dose Indicator for use with Forest’s
proprietary product containing the active ingredient Flunisolide in an
HFA formulation.
As the CFC to HFA transition deadline for pressurized metered dose
inhalers (MDIs) approaches, Flunisolide, an existing CFC based inhaled
corticosteroid (ICS) branded as Aerobid®,
has been reformulated with a non ozone depleting propellant to
transition through the CFC phase out. A notable change in Forest’s
Flunisolide HFA product will be the integration of the AEROCOUNT
Dose Indicator to remind patients how much medication remains in their
inhaler.
“The CFC to HFA transition has presented an
opportunity to provide patients with the added benefit of our dose
counting technologies”, explains Mark
Pickard, VP and General Manager of Trudell Medical International. “We
are extremely pleased to have signed a multi-year supply agreement with
Forest and to compliment their efforts to bring Flunisolide HFA through
the transition.”
Earlier this year Freedonia forecast the inhalation market to have a
healthy growth rate of 9% through to 2012 and that MDIs will see
significant gains from improvements to propellant safety and particle
manufacturing technologies. Despite the range of respiratory delivery
innovations, the MDI is likely to maintain its market dominance by being
a low cost and easy-to-use platform. The AEROCOUNT Dose
Indicator is designed to maintain the same look and feel of the MDI with
the added benefit of tracking the number of doses remaining.
About Trudell Medical International
Trudell Medical International has a 25 year history in creating
innovative aerosol drug delivery products that are distributed in over
90 countries around the world. With the first patent dating back to
January 1998, Trudell Medical International’s
intellectual property in dose counting consists of over 50 issued
patents and patents pending. Leveraging over a decade of development and
commercialization effort in dose counting, Trudell Medical International
is able to provide pharmaceutical partners with a turnkey solution. In
addition to the AEROCOUNT (www.aerocount.com)
Dose Counters and Indicators, Trudell Medical International produces the AEROCHAMBER®
Brand of Valved Holding Chambers, AEROECLIPSE®
II Breath Actuated Nebulizer and a range of other devices for
respiratory disease management. For more information visit www.trudellmed.com
About Forest Laboratories
Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical
company with a long track record of building partnerships and developing
and delivering products that make a positive difference in people’s
lives. In addition to its well-established franchises in therapeutic
areas of the central nervous and cardiovascular systems, Forest’s
current pipeline includes product candidates in all stages of
development and across a wide range of therapeutic areas. The company is
headquartered in New York, NY. To learn more about Forest Laboratories,
Inc., visit www.FRX.com.
See the original story at: http://eon.businesswire.com/releases/trudell_medical/medical_international/prweb1374124.htm
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1aZXRhLU1hZ24tUHJvZi1TcXVhLVNpbmctWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
